ÂÜÀòÂÒÂ×

Alph Bingham, Ph.D. is a pioneer in the field of open innovation and an advocate of collaborative approaches to research and development. He is co-founder, and former president and chief executive officer of InnoCentive Inc. Alph spent more than 25 years with Eli Lilly and Company and brings deep experience in pharmaceutical research and development, research acquisitions and collaborations, and R&D strategic planning.

He was instrumental in creating and developing Eli Lilly's portfolio management process as well as establishing the divisions of Research Acquisitions, the Office of Alliance Management, and e. Lilly, a business innovation unit that incubated a wide range of new ventures that exploit open networks, including InnoCentive, YourEncore, Inc., Coalesix, Inc., Maaguzi, Inc., Indigo Biosystems, Seriosity, Chorus, and Collaborative Drug Discovery, Inc.

He currently serves on the Board of Directors of InnoCentive, Fast Track Systems, Inc., and Collaborative Drug Discovery, Inc.; the advisory boards of Navitas Pharma and the Center for Collective Intelligence (MIT), the Business Innovation Factory, and as a member of the board of trustees of the Bankinter Innovation Foundation in Madrid. He serves as a Visiting Scholar at the National Center for Supercomputing Application at the University of Illinois at Champaign-Urbana. He is also the former chairman of the Board of Editors of the Research-Technology Management Journal.

Dr. Bingham was the recipient of The Economist's Fourth Annual Innovation Summit "Business Process Award" for InnoCentive. He was also named as one of Project Management Institute's "Power 50" leaders in October 2005. Dr. Bingham currently participates in the Monitor Talent speaker network. Alph received a B.S. in chemistry from Brigham Young University and a Ph.D. in organic chemistry from Stanford University.